Format

Send to

Choose Destination
BMC Cancer. 2016 Aug 20;16(1):660. doi: 10.1186/s12885-016-2692-4.

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.

Author information

1
CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain. dierssent@unican.es.
2
University of Cantabria - IDIVAL, Santander, Spain. dierssent@unican.es.
3
CIBER Epidemiologia y Salud Publica (CIBERESP), Madrid, Spain.
4
University of Cantabria - IDIVAL, Santander, Spain.
5
Department of Obstetrics and Gynecology, Nuevo Belén University Hospital, Madrid, Spain.
6
Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
7
Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain.
8
Servei d'Oncologia Mèdica, Hospital del Mar, Barcelona, Spain.
9
Cancer Research Program IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
10
Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, and University of Barcelona, Barcelona, Spain.
11
Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
12
Área de Medicina Preventiva y Salud Pública, Departamento de Ciencias Biomédicas, Universidad de León, León, España.
13
Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS), Universidad de León, León, España.
14
Navarra Public Health Institute, Pamplona, Spain.
15
Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
16
IUOPA, Universidad de Oviedo, Oviedo, Spain.
17
Universidad de Huelva, Huelva, Spain.
18
Centro de Investigación en Salud y Medio Ambiente (CYSMA), Huelva, Spain.
19
Area de Cáncer y Salud Pública, Fundación FISABIO- Salud Pública, Valencia, Spain.
20
Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia and Descriptive Epidemiology, Genetics and Cancer Prevention Group [Girona Biomedical Research Institute (IdIBGi)], Catalan Institute of Oncology, Girona, Spain.
21
Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
22
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
23
Onkologikoa- Oncology Institute Gipuzkoa, San Sebastian, Spain.
24
Sección de Oncología, Complejo Asistencial Universitario de León, León, Spain.
25
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.

Abstract

BACKGROUND:

The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors).

METHODS:

In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics.

RESULTS:

In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers.

CONCLUSION:

Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers.

KEYWORDS:

Breast cancer; HER2 positive breast cancer; Hormone receptor positive breast cancer; Non-steroidal anti-inflammatory drug; Triple negative breast cancer

PMID:
27542890
PMCID:
PMC4992258
DOI:
10.1186/s12885-016-2692-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center